Neuronetics to Present at The JMP Securities Life Sciences Conference

Rhea-AI Summary

Neuronetics, a medical technology company listed on NASDAQ under the symbol STIM, will present at The JMP Securities Life Sciences Conference on June 17, 2021, at 10:00 AM ET. CEO Keith Sullivan and CFO Steve Furlong will lead the discussion. A live audio webcast will be available on the company's investor relations page, with an archive accessible for 90 days post-event. Neuronetics focuses on developing products like the NeuroStar® Advanced Therapy System, a TMS treatment approved by the FDA for major depressive disorder.

MALVERN, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate at The JMP Securities Life Sciences Conference. The Company is scheduled to present on Thursday, June 17, 2021 at 10:00am ET.

A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com. A replay of the webcast will be archived on the website for approximately 90 days.

About Neuronetics

Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at www.neuronetics.com.

Investor Contact:

Mike Vallie or Mark Klausner
Westwicke Partners
443-213-0499
ir@neuronetics.com

Media Contact:

Chelsey Manko
Vault Communications
610-455-2778
cmanko@vaultcommunications.com

FAQ

What is the date of Neuronetics' presentation at The JMP Securities Life Sciences Conference?

Neuronetics will present on June 17, 2021.

Who will represent Neuronetics at The JMP Securities Conference?

Keith Sullivan, CEO, and Steve Furlong, CFO, will represent Neuronetics.

How can I access the webcast for Neuronetics' conference presentation?

The webcast can be accessed on Neuronetics' investor relations page.

What is the NeuroStar® Advanced Therapy System?

It is a non-invasive TMS treatment for major depressive disorder.

Is NeuroStar approved by the FDA?

Yes, NeuroStar is FDA-cleared for treating major depressive disorder.